Molecure SA ("MOC")
Climate Impact & Sustainability Data (2022, 2024, H1 2024)
Reporting Period: 2022
Environmental Metrics
Climate Goals & Targets
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2024
Environmental Metrics
Climate Goals & Targets
Short-term Goals:
- First patient dosed in the KITE Phase II PoC study (expected March)
- Interim data analysis by an independent unblinded committee after completion of dosing of approx. 50 patients with lung sarcoidosis (2024 / early 2025)
- Reaching the therapeutic dose (Ph2RD) (end of 2024 / early 2025)
- Following the implementation of AI tools into our drug discovery process: nomination of the first preclinical development candidate generated by AI engine (2024/2025)
- Signing a revenue generating collaboration or licensing agreement in one of the clinical programs or the mRNA platform (mid-late 2024).
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: H1 2024
Environmental Metrics
Climate Goals & Targets
Short-term Goals:
- Interim data analysis of OATD-01 in sarcoidosis (mid 2025)
- Last patient dosed in KITE Phase II PoC study (H1 2026)
- Reaching therapeutic dose (Ph2RD) for OATD-02 (H1 2026)
- Nomination of first preclinical development candidate generated by AI engine (H1 2025)
Environmental Challenges
- Challenging patient enrolment in OATD-01 Phase 2 study due to rare disease and eligibility criteria.
Mitigation Strategies
- Implementation of a revised study patient enrolment strategy including F2F meetings with investigators and patient advocacy groups, different strategies for US and EU/UK adapted to healthcare systems, direct advertising, and a planned F2F seminar for referring physicians in the UK.